T
he effect of pneumococcal conjugate vaccine-7 (PCV-7) in reducing pneumococcal nasopharyngeal (NP) carriage in very low-birth-weight (VLBW) infants has not been studied. Our primary objective was to characterize NP carriage of Streptococcus pneumoniae in a group of VLBW infants (weight, 401-1500 g) before administration of the first PCV-7 vaccine (prevaccine) and at 4 to 6 weeks after a 3-dose PCV-7 primary series (postvaccine). We also investigated the correlation between vaccine-induced pneumococcal IgG antibody level and pneumococcal NP carriage after PCV-7 (postvaccine).
Methods. Very low-birth-weight infants who participated in a PCV-7 immunogenicity study 1 were enrolled from 4 National Institute of Child Health and Human Development Neonatal Research Network sites (Detroit, Michigan, Rochester, New York, Dallas, Texas, and Birmingham, Alabama). The study was approved by Neonatal Research Network and each site's institutional review board. Written informed consent was obtained from each subject's parent/guardian. Infants received PCV-7 at approximately 2, 4, and 6 months of age.
Nasopharyngeal cultures were obtained at the prevaccine and postvaccine visits. Antimicrobial susceptibility testing of all pneumococcal isolates was performed.
Pneumococcal isolates were serotyped at the Centers for Disease Control and Prevention, Atlanta, Georgia. Serotypes 4, 6B, 9V, 14,18C, 19F, and 23F were classified as vaccine serotypes (VT). Other serotypes were classified as non-VT (NVT).
Antipneumococcal antibodies 2 against 7 VT were measured at the postvaccine visit, and 0.15 µg/mL or greater was chosen as a possible measure of protective level. 3 Descriptive statistics were used to characterize the study subjects with regard to birth weight, gestational age at birth, and chronologic age at swab collection, as well as serotype and antimicrobial susceptibilities of pneumococcal isolates.
Results.
A total of 123 of 135 infants enrolled had at least 1 NP swab obtained; 71 had prevaccine and 102 had postvaccine NP swab cultures. Fifty infants had both prevaccine and postvaccine NP swabs. Most (44 of 71;62%) had a prevaccine NP swab done while in the neonatal intensive care unit, whereas all but 1 had postvaccine NP swab done after hospital discharge.
The median gestational age of 123 infants was 28 weeks (range, 23-32). The median chronologic ages at prevaccine and postvaccine NP swab collections were 2 (range, 1-3) and 8 months (range, 6-10), respectively. S pneumoniae was isolated in 4.2% (3 of 71) prevaccine and 12.7% (13 of 102) postvaccine samples. One infant had positive prevaccine and postvaccine NP cultures with 2 different serotypes; another colonized at prevaccine had a negative postvaccine NP culture. Of the 50 infants with both prevaccine and postvaccine NP swabs, 49 had negative prevaccine NP cultures, of whom 8 became colonized at the postvaccine visit (all NVT) (Table) .
Serotyping was done on 15 of 16 isolates (Table) . One prevaccine isolate was a VT; all 12 postvaccine isolates were NVT. Antibiotic susceptibility 4 (Table) revealed 1 prevaccine isolate that was resistant to erythromycin. Of 12 postvaccine isolates, 2 (19A) were resistant to 4 antibiotics, 1 (35B) to penicillin, and 1 (nontypeable) to erythromycin.
Serum anticapsular IgG antibody levels to 7 VT were available for 100 infants who had postvaccine NP swabs. Antipneumococcal antibody levels greater than 0.15 µg/mL were achieved in 88% to 99% of participants and varied by serotype. Since all postvaccine pneumococcal isolates were NVT, assessment of NP carriage status based on antibody levels could not be performed.
Comment.
The pneumococcal NP carriage rate of 12.7% in our very low-birth-weight infants after PCV-7 vaccination was lower than previously reported during the pre-PCV-7 5 and early post-PCV-7 6 eras and was exclusively owing to NVT. Our findings also support the recent observation that NVT serotype 19A is becoming more prevalent. An expanded PCV such as PCV-13 which includes 6 additional serotypes (1, 3, 5, 6A, 7F, and 19A) may change that. Regardless of serum pneumococcal anticapsular antibody levels, all postvaccine pneumococcal NP isolates were NVT, suggesting protection against VT NP carriage at 4 to 6 weeks after the vaccine period. 
